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Abstract
The expression of N-glycolylneuraminic acid (Neu5Gc) and the cytotoxic T cell (CT) carbohydrate can impact the severity of
muscular dystrophy arising from the loss of dystrophin in mdx mice. Here, we describe the expression of these two glycans
in skeletal muscles of dogs and humans with or without dystrophin-deficiency. Neu5Gc expression was highly reduced
(.95%) in muscle from normal golden retriever crosses (GR, n = 3) and from golden retriever with muscular dystrophy
(GRMD, n = 5) dogs at multiple ages (3, 6 and 13 months) when compared to mouse muscle, however, overall sialic acid
expression in GR and GRMD muscles remained high at all ages. Neu5Gc was expressed on only a minority of GRMD satellite
cells, CD8+ T lymphocytes and macrophages. Human muscle from normal (no evident disease, n = 3), Becker (BMD, n = 3)
and Duchenne (DMD, n = 3) muscular dystrophy individuals had absent to very low Neu5Gc staining, but some punctate
intracellular muscle staining was present in BMD and DMD muscles. The CT carbohydrate was localized to the
neuromuscular junction in GR muscle, while GRMD muscles had increased expression on a subset of myofibers and
macrophages. In humans, the CT carbohydrate was ectopically expressed on the sarcolemmal membrane of some BMD
muscles, but not normal human or DMD muscles. These data are consistent with the notion that altered Neu5Gc and CT
carbohydrate expression may modify disease severity resulting from dystrophin deficiency in dogs and humans.
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Introduction
Duchenne muscular dystrophy (DMD) is a severe X-linked
myopathy of childhood that arises from the loss of dystrophin
protein expression in cardiac and skeletal muscles[1,2]. Becker
muscular dystrophy (BMD) also results from mutations or
deletions in the dystrophin gene, but BMD mutations allow for
expression of partially functional dystrophin protein and are
typically associated with phenotypically milder muscle disease than
is seen in DMD. A number of animal models have been used to
better define disease pathophysiology and treatments that might
ameliorate DMD and BMD[3]. The model used to test most MD
therapies is the mdx mouse, which lacks dystrophin in cardiac and
skeletal muscles due to a nonsense point mutation in exon 23 of
the dystrophin gene[4,5]. Spontaneous mutations and deletions in
the dystrophin gene also occur in dogs[6–8] and cats[9–11]. The
Golden Retriever Muscular Dystrophy (GRMD) dog is one such
DMD model that has been bred for research purposes[6,12].
GRMD dogs harbor a single base pair change in the 39 consensus
splice site of intron 6, resulting in the skipping of exon 7 and an
out-of-frame transcript with a stop codon immediately down-
stream[6,13]. GRMD dogs model a number of features of muscle
pathophysiology found in DMD, including increased muscle
membrane fragility, weakened muscle force, increased force
decrement in response to eccentric contractions, altered pelvic
and limb joint angles arising from combined muscle hypertrophy
and atrophy, increased muscle inflammation, cardiomyopathy,
loss of ambulation and premature death[6,12,14–20]. In addition,
treatment of GRMD dogs with corticosteroids, which can prolong
ambulation in DMD[21], yields improvement in muscle outcome
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measures[22]. Thus, while each animal model has its own
advantages, GRMD dogs are generally thought to be a very good
model of the more severe aspects of DMD pathophysiology and
therefore potentially more appropriate for testing DMD therapies.
It is clear from a number of recent studies that glycosylation of
the sarcolemmal membrane with particular carbohydrate struc-
tures can impact muscle membrane integrity and disease[23–27].
One such modifier of disease severity in the mdx mouse model is
the Cmah gene[28]. Cmah encodes the CMP-Neu5Ac hydroxylase,
the only enzyme known to hydroxylate the sugar nucleotide
precursor for sialic acids at the 5-N-acyl position, converting
CMP-Neu5Ac to CMP-Neu5Gc[29,30]. The twenty or so
sialyltransferases in mammals utilize these substrates to add sialic
acids to glycoproteins and glycolipids[31]. In all mammals studied
to date, save humans, Cmah encodes an active enzyme that can
result in Neu5Gc on glycoproteins and glycolipids. In mouse
skeletal and cardiac muscle, Neu5Gc and Neu5Ac are the
predominant sialic acid forms[28]. About 2–3 million years ago,
after the divergence of humans from the great apes, a 92 base pair
deletion in exon 6 of the human CMAH gene led to its inactivation
from a resulting frame shift[32], and as a result all humans lack the
biosynthetic ability to create Neu5Gc[33,34]. Deletion of mouse
Cmah to reiterate this event in human evolution does not grossly
impact muscle function, but loss of Cmah in mdx mice leads to
more severe disease pathology, resulting in additional reductions in
the strength of diaphragm and cardiac muscles as well as reduced
lifespan[28]. While many other modifiers of disease severity occur
in mdx mice, for example integrin a7[35], utrophin[36,37],
MyoD[38], sarcospan[39,40] and telomerase[41], this is the first
example of a disease modifier where the genetic change actually
reiterates a human-specific genetic event.
As Cmah2/2mdx mice show more severe disease severity than
mdx animals, the question arises as to how Neu5Gc may impact
disease in other animal models, such as dogs and cats. One
comparative study of muscle glycolipids has shown that dog
muscle has very low Neu5Gc levels, with Neu5Gc comprising 2%
of total sialic acid as compared to much higher levels in the mouse,
cow and monkey[42]. This raises the possibility that dog muscles
are hypomorphic for Neu5Gc, even though they appear to express
a functional canine CMAH gene.
Another carbohydrate structure that can modify muscular
dystrophy is the Cytotoxic T cell (CT) carbohydrate (GalNAcb1-
4[Neu5Ac/Gca2-3]Galb1-4GlcNAc-)[43–45]. The CT carbohy-
drate is normally confined to the neuromuscular junction in adult
mouse and human skeletal muscle, with additional expression in
intramuscular capillaries[46,47]. The enzyme that defines the
synaptic expression of the CT carbohydate is encoded by the
Galgt2 gene (also called b4Galnt2). Galgt2 encodes a b1-4GalNAc
glycosyltransferase that creates the terminal b1-4GalNAc linkage
on the CT carbohydrate[48–50]. Overexpression of Galgt2 in
mouse skeletal myofibers stimulates the glycosylation of a
dystroglycan with the CT carbohydrate and induces the ectopic
overexpression of normally synaptic dystroglycan-binding pro-
teins, including utrophin, laminin a4, laminin a5 and agrin[48,51–
56]. Such overexpression of Galgt2 can ameliorate muscular
dystrophy in three different mouse models of muscular dystrophy,
the mdx model for DMD[55], the Sgca2/2 model for
LGMD2D[53] and the dyW model for MDC1A[52]. Galgt2
overexpression correlates with increased laminin and agrin
binding to a dystroglycan[54] and with increased resistance of
skeletal muscles to injury resulting from eccentric contractions[24].
Despite the demonstrated functional effects of these carbohy-
drates on muscle disease, there is no published information on CT
carbohydrate expression and little to no information on Neu5Gc
expression in BMD or DMD muscles or in golden retriever (GR)
or GRMD muscles. As low levels of Neu5Gc and CT carbohy-
drate correlate with more severe disease in mice, we asked here
whether a similar relative deficit might potentially contribute to




mdx and wild type (both in a C57Bl/10 genetic background)
mice were bred at Nationwide Children’s Hospital in accordance
with protocols approved by the Institutional Animal Care and Use
Committee and specifically approved for use in this study (Permit
AR07-00033). The full name of this committee is the ‘‘Institutional
Animal Care and Use Committee at Nationwide Children’s
Hospital’’.
GR crosses and GRMD dogs were bred at University of North
Carolina, Chapel Hill, in accordance with protocols approved by
their Institutional Animal Care and Use Committee under a
protocol that included the experiments described in this study
(Permit 06-338). The full name of this committee is the
‘‘Institutional Animal Care and Use Committee at the University
of North Carolina’’.
Blinded sections from human muscle biopsies were obtained
from clinical specimens archived as part of the United Dystrophi-
nopathy project in accordance with approval from the Institutional
Review Board (IRB) at Nationwide Children’s Hospital. The full
name of this committee is the ‘‘Institutional Review Board at
Nationwide Children’s Hospital’’. All samples were obtained with
patient’s written informed consent. As part of the consent process
approved by the IRB, we received written consent from guardians
on behalf of children/minors. Dated and signed consent forms
were archived.
Mice
mdx and wild type (both in a C57Bl/10 genetic background)
mice were bred at Nationwide Children’s Hospital in accordance
with protocols approved by the Institutional Animal Care and
Use Committee. mdx mice were originally obtained from
Jackson Laboratory and Cmah2/2 mice and Cmah2/2mdx
mice were generated previously[28,57]. Muscles from mdx mice
treated with Adeno associated virus (AAV) vector to overexpress
the human GALGT2 gene (also termed B4GALNT2), using
rAAV(rh.74).MCK.GALGT2, were utilized from a previous
study[24].
Dogs
GR crosses and GRMD dogs were bred at University of North
Carolina, Chapel Hill, in accordance with protocols approved by
their Institutional Animal Care and Use Committee. Assessment
of severity of muscle disease was measured by observation of gait
and ambulation as well as measures of tibiotarsal joint (TTJ) angle
and maximal tibiotarsal flexion and extension, per previous
studies[14,16,19]. For sake of defining disease severity in these
GRMD dogs, we characterized several phenotypic features. Ringo
and Napoleon were characterized as ‘‘severe’’ based on TTJ
extension tetanic force and TTG angles below 1 N/kg and 145u,
respectively, while values above these levels were associated with a
‘‘mild’’ phenotype in Tico, Jane and Summer (Table S1). Biopsy
or necropsy samples of cranial sartorius (CS) and vastus lateralis
(VL) muscles were serially obtained at 3, 6 and 13 months of age.
Methods to measure muscle physiology and other measures
Neu5Gc Expression in Human and Canine Muscle
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describing dystrophic changes have been described in previous
studies[16,19].
Human muscle biopsies
Blinded sections from human muscle biopsies were obtained
from clinical specimens archived as part of the United Dystrophi-
nopathy project in accordance with approval from the Institutional
Review Board. Normal human muscles were from a 55 year-old
(yo) male, a 5yo male and a 6yo female; DMD muscles were taken
from 6 and 5yo males and BMD muscles from 11yo, 35yo and
67yo males. Biopsies were taken from the quadriceps muscle in
most instances. ‘‘Normal’’ human samples were defined as biopsies
where no myopathy or evidence of inflammation was present. For
all normal cases, dystrophin protein expression was verified as
being positive, and for all DMD cases, dystrophin protein
expression was verified as being negative. DMD cases arose from
a duplication of exons 29–43, c.3603+2T.C splice site mutation,
or a duplication of exons 3–6. The three BMD cases arose from an
intron 11 c.1331+17770C.G pseudoexon mutation (leading to
mutant RNA r.1331_1332ins1331+17691_1331+17769 (case BZ),
with loss of ambulation at age 23, an exon 2 c.40_41delGA
frameshift mutation, with ambulation until at least 36 (case KG),
and an intron 25 c.3432+3730G.T pseudoexon mutation,
leading to mutant RNA r.3432_3433ins3432+3663_3432+3728,
with ambulation until at least 67 (case RS). None of the cases were
treated with steroids prior to biopsy.
Immunostaining
Human muscle biopsies and mouse skeletal muscles were snap
frozen in liquid nitrogen-cooled isopentane; dog muscle biopsies
were frozen in liquid nitrogen-cooled SUVA34A (Freon analogue).
8 mm cross-sections of all skeletal muscles were cut on a cryostat.
For staining with antibody to glycans bearing N-glycolylneur-
aminic acid (Neu5Gc, affinity purified chick IgY; Sialix) or non-
immune chick IgY control (Sialix), sections were blocked in
phosphobuffered saline (PBS) with 10% human serum that was
confirmed to be Neu5Gc-free. Sections were incubated with anti-
Neu5Gc or control antibody (1:500 or 1:1000) in blocking solution
(10% human serum) overnight at 4uC, washed in PBS, incubated
with donkey anti-chicken IgY secondary antibody conjugated to
FITC (1:250; 703-485-155, Jackson Immunoresearch), washed
again in PBS and mounted in glycerol with paraphenylenedia-
mene to inhibit fluorescence quenching. For Maackia amurensis
agglutinin (MAA) staining, sections were blocked in 5% bovine
serum albumin (BSA) in PBS. Sections were incubated with FITC-
conjugated MAA (10 mg/mL, EY laboratories, F-7801), washed in
PBS and then mounted. All MAA staining could be blocked by
addition of exogenous excess sialic acid to demonstrate lectin-
binding specificity. Anti-Neu5Gc immunostaining could be
blocked with either 10% chimpanzee serum, which has excess
Neu5Gc, or by pre-treating sections with mild periodate to destroy
the immunogenic side chain of Neu5Gc. None of these methods,
or staining with non-immune chick IgY serum, differed from the
control images shown.Wisteria floribunda agglutinin (WFA) linked to
FITC was used to stain muscle at 2 mg/mL (EY Laboratories, F-
3101), with 5% BSA in PBS used as a blocking agent. CT1 and
CT2 staining was performed as previously described using
antibody purified from hybridoma supernatant[58]. Staining for
CT1, CT2 or control anti-mouse IgM(only) was blocked in 3%(v/
v) BSA in PBS for one hour, followed by incubation with
hybridoma supernatant (used straight or diluted 1:2) overnight.
Sections were then washed in PBS and incubated in goat anti-
mouse IgM(only) conjugated to Cy2 (115-225-020, Jackson
ImmunoResearch).
For double immunostaining, sections were first stained over-
night at 4uC with anti-Neu5Gc or control-specific chicken IgY
after blocking in 10% (Neu5Gc-free) human serum, or with CT1
or CT2 after blocking in 5 mg/mL BSA, as described above. For
Pax7 co-staining, sections were fixed in 2% paraformaldehyde.
After blocking in 10% human serum, sections were then incubated
overnight mouse-anti Pax7 (clone P3U1, Developmental Studies
Hybridoma Bank), followed by species- and isotype-specific
fluorophore-conjugated secondary antibodies for one hour. Pax7
antibody was a generous gift from Michael Rudnicki (Ottawa
Health Research Institute). For all other anti-Neu5Gc or anti-CT
co-stains, sections were incubated overnight with both primary
antibodies without fixation, washed for one hour and incubated
with the appropriate secondary antibodies as above. All sections
were washed and placed in mounting medium containing with
DAPI. Co-staining antibodies used in dog were mouse anti-
chicken Pax7 (Developmental Studies Hybridoma Bank, clone
P3U1), mouse anti-dog CD4 (AbD Serotec, MCA1998S), rat anti-
dog CD8 (AbD Serotec, MCA1039GA), mouse anti-dog CD11b
(AbD Serotec, MCA1777S), mouse anti-dog CD21 (AbD Serotec,
MCA1781R), mouse anti-human b spectrin (Novus, NB300-574)
or mouse anti-rat embryonic myosin (NovaCastra, NCL-MHCd).
Co-staining antibodies used in human were mouse anti-chicken
Pax7 (Developmental Studies Hybridoma Bank, clone P3U1),
FITC-conjugated rabbit anti-human CD4 (BD Bioscience,
550628), FITC-conjugated mouse anti-human CD8 (AbD Serotec,
MCA1039GA), rabbit anti-human CD11b (Abcam, ab52478),
mouse anti-human b spectrin (Abcam, ab2808), mouse anti-rat
embryonic myosin (eMyosin; NCL-MHCd, NovaCastra), rabbit
anti-human calnexin (Sigma, C4731), rabbit anti-human clathrin
(Cell Signaling, P1663), rabbit anti-human LAMP1 (Sigma,
L1418) or mouse anti-human 58K Golgi protein (Novus,
NB600-412). Other sections were co-stained with WFA-FITC
and mouse anti-rat embryonic myosin (eMyosin; NCL-MHCd,
NovaCastra). Appropriate fluorophore-conjugated species or
species- and isotype-specific secondary antibodies were obtained
from Jackson Immunoresearch. Imaging was done on a Zeiss
Axiophot epifluorescence microscope using AxioVision LE 4.1
imaging software (Zeiss; Jena, Germany) with fluorescein-, DAPI-,
or rhodamine-specific optics. AAV(rh.74).MCK.GALGT2(human)-
treated mdx muscles were infected for 12 weeks, as previously
described[24]. All images shown in a figure use time-matched
exposures for comparison and were representative of commonly
seen staining patterns. For quantification of cell staining, 5 random
10x images per muscle were taken and counted as previously
described[59].
Western blotting
Western blots for Neu5Gc and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were done and quantified as previously
described using 15 or 30 mg per lane of NP40-extracted skeletal
muscle protein separated on by SDS-PAGE on a 4–12% gradient
gel[60].
Quantification of sialic acids
Quantification of total sialic acid and sialic acid species (relative
Neu5Gc and Neu5Ac levels) was performed with modification from
previously described methods of DMB (1,2-diamino-4,5-methyle-
nedioxybenzene dihydrochloride) derivatization[61]. Briefly, 20–
60 mg muscle tissue was homogenized in 10% PBS, base
treated with 100 mM NaOH at 37uC for 30 minutes, then
neutralized with 100 mM HCl. Small aliquots were taken for
protein concentration determination using a Bradford assay.
Sialic acids were then hydrolyzed with 2 M acetic acid at 80uC
Neu5Gc Expression in Human and Canine Muscle
PLOS ONE | www.plosone.org 3 February 2014 | Volume 9 | Issue 2 | e88226
for 3 hours and passed through a 10 K molecular weight filter.
Flow-through was concentrated and subjected to DMB deriv-
atization at 50uC for 2.5 hours. Samples were then resolved
using high performance liquid chromatography (HPLC) and
Neu5Ac and Neu5Gc peaks quantified, as before[47].
Results
We chose to study two dog muscles, the vastus lateralis (VL) and
the cranial sartorius (CS), because these muscles have been well
documented to undergo differential changes relevant to muscular
dystrophy in GRMD animals[17]. In particular, the CS shows
more muscle necrosis during the neonatal period and subsequent
hypertrophy by 6 months of age, while the VL has a more delayed
pattern of muscle necrosis and regeneration that leads to atrophy
(Figure S1). Muscle biopsies or necropsies from three GR and five
GRMD dogs were used for this study. Of the five GRMD dogs,
two (Ringo and Napoleon) showed severe muscular dystrophy by
six months of age, as evidenced by decreased tibiotarsal joint angle
and decreased force of tibiotarsal joint extension, two well-
described measures of GRMD disease severity[16–18,62], while
three others (Tico, Jane and Summer) were mildly affected, having
measures for these parameters that neared or equaled wild type
dogs despite having the same GRMD genetic defect (Table S1).
We first compared Neu5Gc staining in muscles from 6 month-
old GR (Swiper), mildly affected GRMD (Tico) and severely
affected GRMD (Ringo) dogs (Figure 1A). As expected from the
previously documented low level of Neu5Gc in dog muscle
gangliosides[42], we found very little Neu5Gc staining in GR or
Figure 1. Neu5Gc expression in Golden Retriever cross (GR) and Golden Retriever Muscular Dystrophy (GRMD) dog skeletal muscle
relative to mouse. (A) Neu5Gc-specific affinity-purified chicken IgY was used to stain skeletal muscles from 6 month-old normal Golden Retriever
(GR) or Golden Retriever Muscular Dystrophy (GRMD) dogs. An example of staining from a severely affected and a mildly affected GRMD dog are
shown. (B) Time-matched images in A were compared to normal mouse skeletal muscle immunostained with the same reagents. Non-immune
chicken IgY was used as a control for background staining in A and B. Bar is 200 mm for all panels in A and B.
doi:10.1371/journal.pone.0088226.g001
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GRMD muscle membranes. In addition, there was no Neu5Gc
immunostaining of intramuscular connective tissue in any dog
muscle (Figure 1A). There was some difference in fiber type
between different GR and GRMD muscles, with CS showing a
bias towards more slow fibers than the VL, as has been previously
described[62]. Positively stained GR myofibers showed an uneven
pattern of membrane staining, with some myofibers showing no
staining, while GRMD muscles appeared to have even lower levels
of staining than GR muscles (Figure 1A). While Neu5Gc staining
of muscles from the severely affected GRMD dog appeared to be
reduced relative to staining of the muscles from the mildly affected
GRMD dog, this was not found to be significant when comparing
all sections stained from all GRMD animals (not shown). By
contrast, anti-Neu5Gc immunostaining of normal mouse gastroc-
nemius muscle showed very high and uniform staining of skeletal
myofibers as well as intramuscular connective tissue (Figure 1B).
Staining of muscles with pre-immune chicken IgY (Figure 1A and
1B, control) or secondary antibody alone (not shown) showed no
background immunostaining. Thus, both GR and GRMD
muscles showed very little Neu5Gc expression.
To investigate this further, we determined Neu5Gc levels, as a
fraction of total sialic acids, in skeletal muscles from wild type and
mdx mice and from GR and GRMD dogs (Figure 2). In addition,
we compared Neu5Gc expression on GR and GRMD muscle
glycoproteins to muscles from wild type (Cmah+/+ and Cmah2/2)
mice (Figure S2). In both instances, both GR and GRMD muscles
(CS and VL) expressed a fraction of the signal seen in mouse
muscles (tibialis anterior, soleus and gastrocnemius). Neu5Gc
levels did not exceed 2% of total sialic acids for any GR and
GRMD muscle, while Neu5Gc levels in wild type and mdx mouse
muscles averaged 52–55% (Figure 2). Thus, Neu5Gc levels in all
GR and GRMD muscles were significantly reduced, by at least
95%, relative to mouse muscles (P,0.001, any dog muscle
compared to any mouse muscle in Figure 2). Additionally, pooled
GRMD muscles had a significant reduction in Neu5Gc relative to
GR (1.960.2% of total sialic acid in GR vs. 1.460.1% in GRMD,
P,0.05). Total sialic acid content per mole protein, however, was
not reduced in GRMD muscles compared to GR (not shown).
Reduced Neu5Gc on glycoproteins was evident for both severely
affected and mildly affected GRMD muscles (Figure S2). For
example, Neu5Gc blot signals from all GRMD VL samples was
362% of mouse Cmah+/+ muscle signal and 1666% of GR VL
signal. The low number of GRMD dogs precluded us from
making definitive associations between muscle Neu5Gc levels and
individual (severe versus mild) GRMD phenotypes.
To assess overall sialic acid expression, we also stained muscle
sections from GR and GRMD animals with Maackia amurensis
agglutinin (MAA), a sialic acid-binding lectin that recognizes sialic
acid in a a2-3-linkage[63](Figure S3). GR and GRMD muscles,
from both CS and VL, showed high levels of MAA staining along
skeletal myofiber membranes and within intramuscular connective
tissue. Increased fibrosis was evident from MAA staining of
GRMD CS in a severely affected dog, as was the presence of
hypertrophic skeletal myofibers. Thus, the low expression of
Neu5Gc in GR and GRMD muscle was not due to a reduction in
overall sialic acid levels.
We next performed a longitudinal study of anti-Neu5Gc
staining for three different GRMD dogs, imaged at higher
magnification, to assess expression at 3, 6 and 13 months of age
(Figure 3). Muscles in all three GRMD dogs (GRMD1-3,
Napoleon, Jane and Summer, respectively) showed higher
Neu5Gc staining in mononuclear cells within the muscle than
was seen on GRMD myofibers. There was faint Neu5Gc
expression in some GRMD skeletal myofibers at 6 and 13 months
of age compared to 3 months, however, this staining was not
uniformly present. We stained the same GRMD dog muscles with
MAA to assess relative total a2-3-linked sialic acid levels (Figure
S4). MAA staining was high and relatively constant in both CS
and VL muscles of GRMD dogs at 3, 6 and 13 months of age.
MAA staining showed evidence of increased hypertrophic
myofibers in the CS versus VL at 6 and 13 months, consistent
with previous studies[17].
To further delineate which mononuclear cells expressed
Neu5Gc in GRMD muscles, we triple stained muscle sections
for Neu5Gc, DAPI (to stain nuclei) and markers for Pax7
(Figure 4A), to identify satellite cells, CD11b (Figure 4B), to
identify macrophages, CD4 (Figure 4C), to identify helper T
lymphocytes, or CD8 (Figure 4D), to identify cytotoxic T
lymphocytes. We utilized mouse hybridoma clone P3U1 for
Pax7 staining. A subset of cells that stained for Neu5Gc could be
co-stained with each cell-specific marker used (except CD21, not
shown, which did not stain muscle). Because each of these cell
types co-expressed Neu5Gc, we quantified both the total number
of each cell type per unit area (Figure 5A) as well as the percentage
of each cell type that co-expressed Neu5Gc (Figure 5B). GRMD
muscles showed higher numbers of Pax72, CD42, CD82 and
CD11b2stained cells compared to GR muscles. Aside from CD4+
cells, however, all cell types showed a low percentage of co-
expression with Neu5Gc in GRMD muscles, with only a quarter
to half of Pax7+, CD8+ or CD11b+ cells co-expressing Neu5Gc
(Figure 5B). For CD8 and Pax7, the percentage of cells expressing
Neu5Gc in GRMD muscle was also significantly lower than it was
in GR muscle (not shown).
Figure 2. Quantification of Neu5Ac and Neu5Gc levels in
normal and dystrophin-deficient mouse and dog muscles.
Tibialis anterior (TA) and soleus (Sol) muscles were analyzed from 11
wild type (WT) mice, TA and gastrocnemius (GS) muscles were analyzed
from 8 mdx mice, and vastus lateralis (VL) and cranial sartorius (CS)
muscles were analyzed from 2 golden retriever (GR) and 5 golden
retriever muscular dystrophy (GRMD) dogs. Average Neu5Gc as a
percentage of total sialic acid is shown. Errors are standard deviation
(SD). ***P,0.001, for all dog vs. mouse muscle comparisons.
doi:10.1371/journal.pone.0088226.g002
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We next analyzed Neu5Gc staining of muscle sections from
biopsies of patients with Becker muscular dystrophy (BMD) or
Duchenne muscular dystrophy (DMD) (Figure 6 Figure S5). These
were compared to muscle sections from patients with an initial
complaint that warranted muscle biopsy but where no muscle
pathology could be identified (otherwise ‘‘normal’’ human muscle).
We identified no Neu5Gc staining in normal human muscle,
consistent with previous studies[28]. Unlike previously published
Neu5Gc staining[28], however, we also identified some punctate
intracellular Neu5Gc staining in BMD and DMD muscles. This
was the case in all three DMD and all three BMD biopsies
analyzed (Figure S5). Co-staining of Neu5Gc and b spectrin, a
sarcolemmal membrane marker, showed that most Neu5Gc
staining was localized within skeletal myofibers or near the
sarcolemmal membrane, with greater concentrations being found
within smaller myofibers (Figure 6A). By contrast, there was
minimal to no co-staining of Neu5Gc with CD11b, CD8 or Pax7
in DMD muscle (Figure 6B). The intracellular aggregates of
Neu5Gc within skeletal myofibers often co-stained with clathrin, a
marker for endosomes (Figure 7A). In addition, some co-staining
was evident with 58K Golgi protein, a marker for the Golgi
apparatus (Figure 7B). There was minimal co-staining with
LAMP1, a marker for lysosomes, or with calnexin, a marker for
the endoplasmic reticulum (Figure 7B). Thus, the majority of
Neu5Gc-stained puncta found within skeletal myofibers were co-
stained with a marker for endosomes (Figure 7), suggesting that
Neu5Gc is internalized by endocytosis into dystrophin-deficient
human muscles and concentrated in distinct intramuscular and
perimembranous regions of skeletal myofibers.
Figure 3. Neu5Gc expression in GRMD muscle at different ages. Three different GRMD cases (GRMD1, 2, and 3) were biopsied and muscles
stained for Neu5Gc at 3, 6 and 13 months of age. Time-matched images of staining of the cranial sartorius (A) and vastus lateralis (B) muscles are
shown. Bar is 50 mm for all panels in A and B.
doi:10.1371/journal.pone.0088226.g003
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We next surveyed CT carbohydrate and overall bGalNAc
expression in GR and GRMD muscles, using the CT2 monoclonal
antibody and Wisteria floribunda agglutinin (WFA), respectively
(Figure 8 and Figure S6). In GR muscle, most WFA and CT2
staining was present at the neuromuscular junction (NMJ) (Figure
S5). NMJs were identified by costaining with rhodamine-a-
bungarotoxin, which labels nicotinic acetylcholine receptors
(AChRs). In GRMD muscle, we also identified increased WFA
staining on extrasynaptic regions of the muscle sarcolemmal
membrane, as described previously in mdx mice[64]. WFA
staining was not as abundant in eMyosin-positive myofibers as
in eMyosin-negative myofibers (Figure 8C). In addition, we
identified intense CT2 staining in mononuclear cell infiltrates in
GRMD muscle. Here, CT2 co-stained with CD11b, suggesting
that much of this CT expression was present on macrophages
(Figure 8A). While CT2 co-stained large aggregates of macro-
phages in some muscle regions, an example with only a few
macrophages present is shown here for clarity. CT2 co-stained
with Pax7 far less frequently than with CD11b (Figure 8B). These
data are similar to immunostaining results in mdx muscle[55] and
show that CT carbohydrate expression can be increased in
GRMD muscle relative to GR.
Last, we determined CT carbohydrate expression in DMD and
BMD muscles, compared to normal human muscle (Figures 9, 10
and S7). We had previously demonstrated that CT2 shows a
binding preference for the CT carbohydrate when Neu5Gc is the
sialic acid present, while CT1 shows a binding preference for CT
carbohydrates containing Neu5Ac[47]. We first compared CT1
and CT2 staining in DMD (Figure 9A) and normal human
(Figure 9B) muscle to determine if CT1 would stain more strongly,
as humans do not make Neu5Gc[32] (Figure 9). We also stained
mdx muscles (Figure 9C) that had been infected with
AAV(rh.74).MCK.GALGT2[24] to overexpress the CT carbohy-
drate. As expected, CT1 stained human muscle, but CT2 did not,
while both antibodies stained AAV-GALGT2-infected mouse
muscle (Figure 9). Normal human and DMD muscles did not
show CT1 staining along the sarcolemmal membranes of
myofibers, which were co-labeled with b spectrin, but some
staining was evident in mononuclear cells (co-stained with DAPI)
and also in peripheral nerve (Figure 10). All three BMD muscle
biopsies, by contrast, showed increased CT1 staining along
myofiber membranes (Figure 10, Figure S7). While it is impossible
to generalize with only three cases, we observed at least some
CT1-stained positive fibers in all three BMD cases used, and these
cases ranged from relatively severe (loss of ambulation at 23) to
relatively mild (ambulant at 67). In Figure S7, each BMD case is
presented, respectively, with severity ranging from severe on the
left to mild on the right.
Figure 4. Neu5Gc immunostaining of satellite cells, T lymphocytes and macrophages in GRMD skeletal muscle. GRMD muscle (cranial
sartorius) was triple stained for Neu5Gc (green), Pax7 (A), CD11b (B), CD4 (C), CD8 (D) (all red), and DAPI (blue). Arrows indicated co-staining of
Neu5Gc and Pax7 (in A), CD11b (in B) or CD4 (in C). Bar is 100 mm (A) and 50 mm (B–D) for all panels.
doi:10.1371/journal.pone.0088226.g004
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Discussion
Both N-glycolylneuraminic acid (Neu5Gc), which requires the
Cmah gene for its synthesis, and the Cytotoxic T cell (CT)
carbohydrate, which requires the Galgt2 gene for its synthesis, can,
when altered, affect the severity of muscular dystrophy in mdx
mice; Deletion of Cmah[28] or Galgt2 (Xu et al., in preparation)
increases severity of muscular dystrophy in the mdx mouse,
decreasing lifespan and sometimes also muscle strength, while
increasing Galgt2 can ameliorate muscular dystrophy, increasing
resistance of muscles to injury[24,55]. Here we have analyzed the
expression of these two carbohydrates in patients with DMD and
BMD and in GR and GRMD dogs. Both humans and dogs with
dystrophin deficiency can show a range of disease severity,
however, these phenotypes are generally more severe than those
exhibited by the mdx mouse. All human cells lack a functional
CMAH gene and therefore cannot synthesize Neu5Gc[32,65]. The
data presented here demonstrate that Golden Retriever dog
muscles also show little to no Neu5Gc expression (Figs. 1–3),
despite lacking a human-like inactivating mutation in the canine
CMAH gene. The low level of Neu5Gc found in skeletal muscle is
consistent with a recent study showing little to no canine CMAH
gene expression in cell lines made from Western dog breeds[66].
These data support the possibility that reduced Neu5Gc levels in
GRMD dog muscles may contribute to their worsened disease
severity relative to mdx mice. Similarly, we found very low levels
of CT carbohydrate expression in both normal human and DMD
muscles (Figure 9 and 10). Surprisingly, BMD muscles show
increased membrane expression of CT carbohydrate (Figure 10).
The fact that CT carbohydrate is not normally expressed in
extrasynaptic membrane of normal, non-diseased, muscle gives an
indication that CT carbohydrate may have a unique function in
the setting of abnormal dystrophin expression. Because Galgt2 and
CT carbohydrate expression are elevated in regenerating muscle,
it is possible that elevated CT carbohydrate expression in BMD
muscles may relate to some aspect of muscle regeneration. As
increased CT carbohydrate can inhibit the development of
muscular dystrophy in mdx mice[24,55], the elevated expression
of the CT carbohydrate in BMD muscles, relative to DMD,
suggests the potential for GALGT2 to contribute to lessened
disease severity in BMD. The expression of a partially functional
dystrophin protein, however, would be the primary effector of
disease severity in BMD[67].
This study is also the first to describe the cellular and subcellular
distribution of Neu5Gc in normal and dystrophin-deficient dog
and human skeletal muscles (Figure 7). In addition to low to absent
Neu5Gc expression on skeletal myofibers, GRMD muscles
expressed Neu5Gc only on a minority of intramuscular satellite
cells, CD8+ T lymphocytes and macrophages (Figure 4 and 5).
Further, almost no such cells were stained for Neu5Gc in DMD
muscles, consistent with loss of CMAH function in humans[32].
By contrast, we did identify intracellular accumulations of Neu5Gc
in DMD and BMD skeletal myofibers (Figure 6). This presumably
reflects the uptake of Neu5Gc by a salvage pathway from the
diet[68,69]. Neu5Gc levels, for example, are particularly high in
red meat[70], and Neu5Gc can be incorporated into cells from
ingested glycoproteins in humans[70] and in Cmah-deficient
mice[57,69]. Here we have shown that intracellular Neu5Gc co-
stains with clathrin and Golgi 58K protein, and to a lesser extent
with LAMP1 (Figure 7). This suggests a possible mechanism, much
of which has been described previously[68], where internalization
of Neu5Gc-containing glycoproteins via endosomes leads to their
transport to the lysosome via the sialin transporter. There,
Neu5Gc present on glycoproteins could be liberated by lysosomal
sialidase. Such a mechanism would ultimately allow recycling of
Neu5Gc into CMP-Neu5Gc, transport into the Golgi, and
reintegration of Neu5Gc into proteins and lipids by sialyltrans-
ferases. The uptake and reincorporation of Neu5Gc into muscle
cell proteins may affect muscle disease by altering muscle
physiology or by increasing Neu5Gc-driven immune reactions.
All humans possess serum antibodies that react with Neu5Gc-
Figure 5. Quantification of CD42, CD82, CD11b2 and Pax72stained cells in GR and GRDM muscle and of Neu5Gc co-staining in
GRMD muscle. (A) Cranial sartorius muscle sections from GR and GRMD dogs were stained with markers for satellite cells (Pax7), T lymphocytes
(CD4 or CD8) or macrophages (CD11b) and quantified for numbers of cells stained per 40X visual field. (B) The percentage of cells co-stained for
Neu5Gc and CD4, CD8, CD11b or Pax7 in GRMD muscles was quantified. Errors are SEM. ***P,0.001, for each GR vs. GRMD comparison in A.
doi:10.1371/journal.pone.0088226.g005
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containing glycans, and these antibodies could increase damage to
Neu5Gc-containing muscle cells[33,71]. Future work will be
required to delineate Neu5Gc’s roles and the possible mechanisms
controlling its functions.
Our findings in dog skeletal muscle suggest that reduced or
absent Neu5Gc in dog muscles may be analogous to Cmah-
deficient mdx mice, which, like GRMD dogs, have relatively
severe muscle disease[28]. GRMD dogs should have no autoim-
mune response to Neu5Gc, as Cmah2/2mdx mice [28]and
humans can[33], but they may share the loss of function effects
of lack of Neu5Gc expression found in Cmah2/2mdx mice and in
DMD patients. The percentage of sialic acid comprising Neu5Gc
was reduced in both GR and GRMD muscles by at least 95%
relative to mouse muscles (Figure 2). Only 1–2% of total sialic acid
was Neu5Gc in any dog muscle studied. Further, Neu5Gc levels in
GRMD muscles were reduced relative to GR. This was evident in
Neu5Gc measurements of total muscle sialic acid (Figure 2),
Neu5Gc immunoblots of muscle glycoproteins (Figure S2) and
Neu5Gc immunostaining of muscle sections (Figure 1).
We also wished to determine if Neu5Gc expression plays a role
in disease severity of individual dogs and the associated dramatic
phenotypic variation. A range of phenotypic features have been
used to allow a general definition of disease severity in GRMD
dogs[62]. In particular, they have lower tibiotarsal joint (TTJ)
tetanic force extension and a plantigrade posture exemplified by
more acute tibiotarsal joint angles[16,19]. Paradoxically, some
muscles (especially flexors) undergo early necrosis and then may
recover or even hypertrophy. Accordingly, TTJ flexor tetanic force
is typically increased in dogs with more severe postural abnor-
malities[62]. In keeping with this paradoxical functional muscle
hypertrophy, the cranial sartorius muscle may become larger as
disease progresses (represented by circumference [mm] divided by
body weight [kg])[17]. While TTJ flexion does not involve the
cranial sartorius muscle, force values tend to track with those of
cranial sartorius hypertrophy. Interestingly, muscle membranes of
hypertrophied muscle fibers appear to be partially protected
against eccentric contraction-induced injury. As a result, the
degree of decrement may actually be reduced in dogs with an
otherwise severe phenotype (Kornegay JN, unpublished data). If
Neu5Gc were playing a role in protecting dystrophic muscles,
increased levels might therefore be expected in the VL of mildly
affected dogs, which might prevent their subsequent atrophy, or
the CS of dogs with a more severe phenotype, which might
contribute to increased hypertrophy. With a small number of
Figure 6. Neu5Gc co-staining with b spectrin, CD11b, CD8 or Pax7 in normal, BMD or DMD humanmuscle. (A) Otherwise normal, Becker
muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD) muscle biopsy sections were stained for Neu5Gc (green), b spectrin (red) and
DAPI (blue). Arrows indicate Neu5Gc puncta in cytoplasmic or perimembranous regions of BMD and DMD skeletal myofibers. (B) DMD muscle was co-
stained for Neu5Gc and CD11b, CD8 or Pax7 (and DAPI). Bar is 50 mm for all panels in A and B.
doi:10.1371/journal.pone.0088226.g006
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Figure 7. Co-localization of Neu5Gc staining with markers for endosomes and Golgi in BMD and DMD muscle. (A) BMD muscle co-
stained for Neu5Gc (green) and clathrin (red), a marker of endosomes. Merged image on right shows overlap of Neu5Gc and clathrin expression in
yellow. Arrow marks several examples of co-staining. (B) DMD muscle co-stained for Neu5Gc (green) with LAMP1, a lysosomal marker, 58K Golgi, a
Golgi marker, or calnexin, and endoplasmic reticulum marker, all in red, and DAPI (blue). Arrow marks region of coincident staining (yellow) for
Neu5Gc and 58K Golgi. Bar is 50 mm for all panels in A and B.
doi:10.1371/journal.pone.0088226.g007
Figure 8. Co-staining of CT carbohydrate with macrophages in GRMD muscle. (A) Single and merged staining for CT2 (green) with CD11b
(red, to mark macrophages) and DAPI (blue). Arrow shows co-incident staining for CT2 and CD11b. (B) Single and merged staining for CT2 (green)
with Pax7 (red, to mark satellite cells) and DAPI (blue). Arrow shows lack of coincident staining for CT2 and Pax7. (C) Examples of WFA staining (green)
with embryonic myosin (red) and DAPI (blue) (two left panels). Examples of control staining for staining shown in A and B using only secondary
antibodies with DAPI (two right panels). Bar is 50 mm for all panels in A, B and C.
doi:10.1371/journal.pone.0088226.g008
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GRMD dogs in this study, we were unable to draw definitive
conclusions regarding the role of Neu5Gc expression in the
individual phenotypes.
Similar to our Neu5Gc studies, we have shown that most DMD
myofibers have very low to absent CT carbohydrate expression
(Figure 9 and 10). By contrast, CT carbohydrate expression was
increased in BMD muscles (Figure 10 and S7). Although these
observations do not establish a causal relationship, they suggest
an association between increased CT carbohydrate and BMD.
CT carbohydrate was also increased in some myofibers and
Figure 9. Comparison of CT1 and CT2 immunostaining in DMD and normal human muscle. CT1 and CT2 were used to immunostain two
different DMD (A) and two different normal human (B) muscle biopsies, compared to secondary antibody control. These were compared to time-
matched images taken from mdx muscles (C), diaphragm (left panel) or tibialis anterior (right panel), that had been infected with
rAAV(rh.74).MCK.GALGT2 for 12 weeks. Bar is 200 mm for all panels in A, B and C.
doi:10.1371/journal.pone.0088226.g009
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macrophages in GRMD muscles (Figure 8), where it may play
additional roles. Further work will be required to understand if
there is a direct relationship between CT carbohydrate expression
and human or canine disease. However, the low expression of
Neu5Gc and CT glycans in DMD and GRMD muscles suggests
that they do not normally have the potential to ameliorate disease
severity in dogs and humans lacking dystrophin protein.
Supporting Information
Table S1 GRMD Dog Functional Data (6 Mos). GRMD
dogs have a range of phenotypic features that allow general
definition of disease severity.1 In particular, they have lower
tibiotarsal joint (TTJ) tetanic extension force2 and a plantigrade
posture exemplified by more acute tibiotarsal joint angles.3
Paradoxically, some muscles (especially flexors) undergo early
necrosis and then may recover or even hypertrophy. Accordingly,
TTJ flexor tetanic force may be increased in dogs with more
severe postural abnormalities.1 In keeping with this paradoxical
functional muscle hypertrophy, the cranial sartorius muscle may
be larger (represented by circumference [mm] divided by body
weight [kg]).4,5 While TTJ flexion does not involve the cranial
sartorius muscle, force values tend to track with those of cranial
sartorius hypertrophy. Interestingly, muscle membranes of hyper-
trophied muscle fibers appear to be partially protected against
eccentric contraction injury. As a result, the degree of decrement
may actually be reduced in dogs with an otherwise severe
phenotype (Kornegay JN, unpublished data). For sake of defining
disease severity in these GRMD dogs, we characterized several of
these features. Ringo and Napoleon were characterized as
‘‘moderate/severe’’, while Tico, Summer, and Jane were ‘‘mild/
moderate,’’ based on TTJ extension tetanic force and TTJ angles
below or above (1 N/kg) and (145u), respectively. 1. Kornegay JN,
Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P, Detwiler DA,
Larsen CA, Grange RW, Bhavaraju-Sanka RK, Tou S, Keene
BP, Howard JF, Jr, Wang J, Fan Z, Schatzberg SJ, Styner MA,
Flanigan KM, Xiao X, Hoffman EP: Canine models of Duchenne
muscular dystrophy and their use in therapeutic strategies. Mamm
Genome 23:85-108, 2012. 2. Kornegay JN, Bogan DJ, Bogan JR,
Childers MK, Cundiff DD, Petroski GF, Schueler RO: Contrac-
tion torque generated by tarsal joint flexion and extension in dogs
with golden retriever muscular dystrophy. J Neurol Sci 166:115–
121, 1999. 3. Kornegay JN, Sharp NJH, Schueler RO, Betts CW:
Tarsal joint contracture in dogs with golden retriever muscular
dystrophy. Lab Anim Sci 44:331–333, 1994. 4. Kornegay JN,
Cundiff DD, Bogan DJ, Bogan JR, Okamura CS: The cranial
sartorius muscle undergoes true hypertrophy in dogs with golden
retriever muscular dystrophy. Neuromuscul Disord 13:493–500,
2003. 5. Kornegay JN, Bogan JR, Bogan DJ, Childers MK,
Grange RW: Golden retriever muscular dystrophy (GRMD):
Developing and maintaining a colony and physiological functional
measurements. In: Duan D (ed). Muscle Gene Therapy: Methods
and Protocols. Methods in Molecular Biology, vol. 709, Humana
Press, New York, 2011, 105–123.
(DOCX)
Figure S1 Muscle damage in mild and severely affected
GRMD muscles at 6 months of age. Hematoxylin and eosin
staining of muscle cross-sections from GR and GRMD muscles.
Cranial sartorius (A–C) and vastus lateralis (D–F) muscles from
one normal dog (Heisenberg, A,D), one mildly affected GRMD
dog (Summer, B, E) and one severely affected GRMD dog
(Napoleon, C, F) are shown. Overall, histopathologic lesions in
these GRMD dogs were in keeping with those we and others have
described. There was small group muscle necrosis and regener-
ation in both the cranial sartorius and vastus lateralis. Each muscle
had features of necrosis, including hyaline fibers and myophago-
cytosis (examples are circled). Myofiber mineralization was only
seen in the cranial sartorius. Evidence of regeneration, with small
basophilic myofibers and numerous central nuclei, was more
pronounced in the vastus lateralis. The regenerative response was
more mature in the cranial sartorius, with an increase in larger
myofibers. Bar is 150 mm for all panels.
(TIF)
Figure 10. Co-staining of CT1 with bspectrin in BMDmuscles. Sections from DMD, BMD and normal human muscle biopsies sections were co-
stained with CT1 (green), b spectrin(red) and DAPI (blue). Merged sarcolemmal membrane staining for CT1 and b spectrin is orange-yellow. PN
represents intramuscular peripheral nerve. Bar is 50 mm for all panels.
doi:10.1371/journal.pone.0088226.g010
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Figure S2 Neu5Gc expression on GR and GRMD
glycoproteins relative to mouse. Western blots of NP-40
extracted muscle protein with anti-Neu5Gc antibody and anti-
GAPDH control. Mouse Cmah+/+ and Cmah2/2 skeletal muscle
lysates were compared to cranial sartorius (CS) and vastus lateralis
(VL) muscles from GR and GRMD dogs that were either mildly or
severely affected. Half the amount of mouse protein as dog protein
is loaded per lane.
(TIF)
Figure S3 High expression of sialic acid in GR and
GRMDmuscle.Maackia amurensis agglutinin (MAA), a lectin that
stains a2,3-linked sialic acid, both Neu5Ac and Neu5Gc, was used
to stain skeletal muscles from 6 month-old Golden Retriever cross
(GR) and Golden Retriever Muscular Dystrophy (GRMD) dogs.
Time-matched images are shown. Bar is 200 mm for all panels.
(TIF)
Figure S4 High sialic acid expression in GRMDmuscles
at different ages. Three different GRMD cases (GRMD1, 2,
and 3-Napoleon, Jane and Summer respectively) were biopsied
and muscles stained for sialic acid using Maackia amurensis
agglutinin (MAA) at 3, 6 and 13 months of age. Time-matched
images of staining of the cranial sartorius and vastus lateralis
muscles are shown. Bar is 50 mm for all panels.
(TIF)
Figure S5 Neu5Gc expression in DMD, BMD and
normal human muscle. Muscle biopsies from Duchenne
muscular dystrophy (DMD), Becker Muscular Dystrophy (BMD),
or otherwise normal human muscle were immunostained with an
antibody specific to N-glycolylneuraminic acid (Neu5Gc) or non-
immune control sera. Each panel represents a different patient
biopsy. Bar is 100 mm for all panels.
(TIF)
Figure S6 Neuromuscular junction staining of bGalNAc
and the CT carbohydrate in GR muscle and elevated CT
staining in GRMD muscle. GR muscle (6mo cranial sartorius)
was co-stained with rhodamine-a-bungarotoxin, to label acetyl-
choline receptors (AChR) concentrated at the neuromuscular
junction, and Wisteria floribunda agglutinin (WFA), which stains b-
linked GalNAc, or CT2, which stains the CT carbohydrate.
Below, GRMD muscle (cranial sartorius) was stained with WFA or
CT2, compared to control secondary antibody alone. Bar is
100 mm for all panels.
(TIF)
Figure S7 CT1 immunostaining of DMD, BMD and
normal human muscle. 3 DMD, 3 BMD, and 2 normal
human biopsies were immunostained with CT1 and compared to
secondary antibody control alone. BMD cases range in severity
from severe (loss of ambulation at 23) to milder (ambulant at 36
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